Giant cell tumours of bone (GCT) are benign bone tumours with a locally aggressive character. Local recurrence is considered the main complication of surgical treatment and is described in up to 50% of patients. Intralesional curettage with the use of adjuvants like phenol or polymethylmetacrylate (PMMA) is recommended as initial treatment, significantly decreasing the risk of recurrence. However, risk factors for local recurrence in skeletal GCT have not yet been firmly established and a golden standard for local therapy remains controversial. The identification of risk factors predisposing for an increased risk of local recurrence. In addition, different surgical techniques are compared to identify the optimal surgical approach for the identified risk factors.Background
Objective
An aneurysmatic bone cyst (ABC) is a benign cystic lesion of bone composed of blood-filled spaces separated by connective septa. The most common treatment is curettage with or without bone grafting. Curettage with bone grafting and Ethibloc injection therapy have a comparable recurrence rate. Ethibloc is a radiopaque alcohol solution of corn protein which is percutaneously injected in the ABC. To compare percutaneous Ethibloc injection (ETHI) with curettage with bone grafting (CUBG) in the treatment of ABC.Introduction
Objective
Comparison of clinical outcome after Percutaneous Vertebro Plasty (PVP) for Osteoporotic Vertebral Compression Fractures (OVCFs) between patients with and without Intra Vertebral Clefts (IVCs). PVP is a common treatment modality for painful OVCFs. Patients presenting with OVCFs with an IVC, also described as avascular necrosis of the vertebral body or intravertebral pseuadoarthrosis, are thought to represent a specific subgroup: filling the cleft might result in immediate and possibly superior pain relief due to stabilization of the excessive mobility associated with an IVC and the risk for cement leakage might be decreased due to its cavitational nature.Objective
Background
